

PET/CT Request Form

Prince of Wales Hospital

Department of Nuclear Medicine and PET



Health

South Eastern Sydney
Local Health District

Level 2 Campus Centre, Barker St, Randwick 2031 NSW Phone 02 9382 2200 Fax 02 9382 2235

Dr E.A. Wegner, A/Prof M.A. Rossleigh, Dr W.Haindl, Dr I. Ho Shon and Associates

NAME	DOB	MRN	M / F
ADDRESS		Mobile	
		Home	
		Work	
URGENCY <input type="checkbox"/> <3 days <input type="checkbox"/> <7 days <input type="checkbox"/> 7-14 days <input type="checkbox"/> non-urgent on or before ___/___/___			
CLINICAL NOTES			
DIABETES No / Diet / NIDDM / Insulin (please call for separate instructions)			
SURGERY date ___/___/___ type _____		RADIOTHERAPY date ___/___/___ site _____	
		CHEMOTHERAPY last ___/___/___ next ___/___/___	

MBS INDICATION (please tick one)

LUNG	<input type="checkbox"/> solitary pulmonary nodule unsuitable for FNAB or failed pathological characterisation (61523)
	<input type="checkbox"/> NSCLC staging for planned curative surgery or radiotherapy (61529)
LYMPHOMA	<input type="checkbox"/> staging of newly diagnosed / previously untreated disease (61620)
	<input type="checkbox"/> evaluation of residual mass or treatment response during or within 3 months of therapy (61622)
	<input type="checkbox"/> restaging of confirmed recurrence (61628)
	<input type="checkbox"/> evaluation of response to 2 nd line chemotherapy prior to stem cell transplant (61632)
SARCOMA (excl GIST)	<input type="checkbox"/> staging of biopsy proven disease considered curable (61640)
	<input type="checkbox"/> restaging of residual or recurrent disease prior to further treatment with curative intent (61646)
HEAD & NECK	<input type="checkbox"/> staging of newly diagnosed or recurrent disease (61598)
	<input type="checkbox"/> restaging of suspected residual disease after definitive treatment (61604)
	<input type="checkbox"/> SCC of unknown primary with cervical node involvement (61610)
MELANOMA	<input type="checkbox"/> restaging of metastatic or recurrent disease (61553)
GIT	<input type="checkbox"/> colorectal cancer restaging of suspected residual, metastatic or recurrent disease (61541)
	<input type="checkbox"/> oesophageal / GEJ cancer staging prior to active therapy (61577)
GYNAE	<input type="checkbox"/> ovarian cancer restaging of suspected residual, metastatic or recurrent disease (61565)
	<input type="checkbox"/> cervical cancer stage at least FIGO IB2, prior to radical XRT or combined Rx with curative intent (61571)
	<input type="checkbox"/> cervical cancer staging of focal recurrence pre salvage chemo or exenteration with curative intent (61575)
BREAST	<input type="checkbox"/> staging of locally advanced (stage III) cancer suitable for active therapy (61524)
	<input type="checkbox"/> suspected locally recurrent or suspected metastatic cancer suitable for active therapy (61525)
BRAIN	<input type="checkbox"/> brain cancer for further therapy planning in suspected residual or recurrent disease (61538)
	<input type="checkbox"/> epilepsy evaluation of refractory disease prior to surgery (61559)
GEP NET Ga68-DOTATATE	<input type="checkbox"/> GEP NET with positive biochemical markers and negative conventional imaging (61647)
	<input type="checkbox"/> GEP NET presurgical assessment of confirmed disease to exclude additional sites (61647)
NON-MBS Scan cost \$400-\$1500	Fluorine-18 tracer: FDG <input type="checkbox"/> FET <input type="checkbox"/> Other <input type="checkbox"/> (please specify)
	Gallium-68 tracer: DOTATATE <input type="checkbox"/> PSMA <input type="checkbox"/> Other <input type="checkbox"/> (please specify)
	<input type="checkbox"/> Research (please complete a separate research study request form)

REFERRING CONSULTANT	Provider no
ADDRESS	Phone
	Fax
	Email
SIGNATURE	DATE ___/___/___